Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens

Summary A series of 55 randomly chosen radical prostatectomy specimens was analyzed for expression of prostate-specific antigen (PSA) by immunohistochemical techniques. Tissue sections were selected in such a manner that in addition to glandular benign prostatic hyperplasia (BPH), one or more different prostatic tumour growth patterns were present. Four monoclonal antibodies, directed against three different PSA epitopes, and one polyclonal anti-PSA antiserum were used. Expression of PSA was compared with that of prostate-specific acid phosphatase (PAP), recognized by two different polyclonal antisera. A critical dilution aimed at a maximum of staining intensity on BPH tissue sections was chosen for all antibodies. Anti-PSA and anti-PAP antisera stained essentially all BPH samples (over 90%). Irrespective of the nature of the antibodies used, PSA expression was found to be decreased in prostatic carcinoma. A clear cut relationship was found between immunoreactivity for PSA and the degree of differentiation of the tumour area. Under the experimental conditions used the PSA monoclonal antibodies stained only 1 out of 10 undifferentiated carcinomas, whereas 50% to 70% of the well- and moderately-differentiated carcinomas showed immunoreactivity. This correlation was less pronounced with the PAP staining pattern. If the PSA antibody titer was raised the percentage of clearly staining undifferentiated carcinomas could be considerably increased (up to 60%–100%), indicating that PSA expression is not absent, but lowered in most (if not all) undifferentiated carcinomas.     

前列腺癌PCNA及AgNOR的表达及临床意义

应用免疫组化（ABC法）和银染技术检测10树前列腺癌和20例前列腺增生患者增殖细胞核抗原（PCNA）和核仁组成区嗜银蛋白（AgNOR）数量变化．结果显示PCNA阳性检出率及AgNOR计数有显著差异（P＜0．01）．且随肿瘤分级增高而增高．随访资料显示PCNA强级（～）者，AgNOR计数高者预后明显低于PCNA弱级（～），AgNOR计数低者．结果提示PCNA，AgNOR可作为前列腺良恶性肿瘤鉴别诊断指标之一，并且与前列腺癌恶性程度有关，对推测预后具有重要参考价值。     

特殊型前列腺增生症的诊治

收治特殊型前列腺增生症１１０例，分别伴有逼尿肌无力、不稳定性膀胱、前列腺结石、膀胱结石、前列腺炎或糖尿病。认为：治疗前认真检查发现特殊前列腺增生症，是提高治愈率、减少并发症的关键步骤之一。     

内皮素-1及受体基因在良性前列腺增生组织中的表达及意义

目的　探讨内皮素 1(ET 1)及受体A、B(ETAR、ETBR)在良性前列腺增生 (BPH)组织中的表达及意义。　方法　应用免疫组化和RT PCR方法检测前列腺组织ET 1及ETAR、ETBRmRNA的表达 ,并与患者临床参数行相关分析。　结果　ET 1、ETARmRNA和ETBRmRNA在BPH组织中的表达 (吸光度A值分别为 0 .94± 0 .0 8、0 .6 4± 0 .0 8、0 .97± 0 .0 8)与正常前列腺组织(0 .5 7± 0 .0 6、0 .37± 0 .0 5、0 .5 1± 0 .0 4 )相比 ,差别均有显著性意义 ,P均 <0 .0 5 ,其中ET 1、ETARmRNA与IPSS、前列腺体积、前列腺尿道长度、前列腺尿道压、最大尿道压呈正相关 ,与最大尿流率、平均尿流率呈负相关。　结论　ET 1和ETAR在BPH中的表达量与膀胱出口梗阻严重程度密切相关。     

雌二醇对去势前列腺癌患者LH脉冲分泌的抑制作用

３例前列腺癌施行双侧睾丸节除术后２－１２周的患，每天肌注苯甲酸雌二醇１ｍｇ，ｄ。治疗前后分别每１０ｍｉｎ采血一次，作７ｈ ＬＨ脉冲分析。结果表明，３例患平均血清ＬＨ水平分别由１７７．５８±３．２０，１３８．３０±５．８３和１４５．８８±３．８２ＩＵ／ＬＧＨＢＴＧＣ １７４．９０±７．６０，１３２．０２±５．７７和１４２．８０±３．６５ＩＵ／Ｌ（Ｐ均＜０．０１），但ＬＨ脉冲幅度和频率无明显变化（     

良性前列腺增生组织中一氧化氮合酶活性的变化

为探讨一氧化氮（ＮＯ）与良性前列腺增生（ＢＰＨ）发病的关系，应用双波长分光光度法测定１５例正常前列腺及２５例ＢＰＨ组织中一氧化氮合酶（ＮＯＳ）活性，并比较不同年龄组的正常前列腺及ＢＰＨ组织中ＮＯＳ活性水平。结果：ＢＰＨ组织中ＮＯＳ活性（９６．７７±２８．０２ｐｍｏｌ．ｍｇ－１．ｍｉｎ－１）明显低于正常前列腺者（２９０．９９±１３０．６８ｐｍｏｌ．ｍｇ－１．ｍｉｎ－１），Ｐ＜０．００１。不同年龄组的正常前列腺组织中ＮＯＳ活性水平与年龄无相关关系。而在５０岁、６０岁和≥７０岁三个年龄组之间的ＢＰＨ组织中ＮＯＳ活性水平有显著性差异，Ｐ＜０．０１，ＢＰＨ组织中ＮＯＳ活性水平随年龄增大呈下降趋势。结果提示前列腺组织中ＮＯＳ活性水平与ＢＰＨ有相关关系，ＮＯＳ活性降低可能是ＢＰＨ的年龄依赖性发病原因之一。     

Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchiectomy

Bone scintigraphy was performed in 16 men with newly diagnosed prostatic carcinoma before orchiectomy as well as 2 weeks and 2 months after operation. The uptake in the lower thoracic and lumbar vertebrae was registered up to 240 min after injection of ^99mTc-MDP and was then calculated for each patient and vertebra. The relative standard deviation in measured uptake due to measuring technique was estimated to be±7%. In eight patients, who had normal bone scintigraphies before orchiectomy, there were no changes in the uptake values after operation. The remaining eight patients had widespread metastatic involvement prior to treatment. Six of these patients showed a so called flare phenomenon in the abnormal vertebrae which means an initial increase in uptake after operation followed by a decreased uptake in response to therapy. One patient had a continuously increased uptake in all the abnormal vertebrae which correlated well with the clinical progression of the disease, while in another patient both reactions were seen. Thus, repeated quantitative bone scintigraphies using ^99mTc-MDP can be made in a reproducible way and can be a useful tool to follow a patient's response to treatment.     

血管生成及其抑制剂在前列腺癌中的研究进展

Angiogenesis plays a key role in progression of prostate cancer. Antigiogenesis becomes a new treament target for prastate cancer. In this review, we focus on the current knowledge of angiogenesis and tumor angiogenesis inhibitor in prastate cancer.     

Early (Stage A) prostatic cancer

Summary This study was performed in order to elucidate some of the problems of incidence, morphology and natural history concerned with Stage A prostatic cancer or prostatic microcarcinoma (PMC).The prostates of 100 patients, treated by subtotal prostatectomy for benign prostatic hyperplasia (BPH), were studied by comparing both routine and step-section techniques. The incidence of PMC was 41% by the former and 86% by the latter technique. Assessment of the size of PMC, as measured by the sum of the two main diameters, resulted in three groups: A₁, A₂, A₃. The last of these may represent a frankly malignant condition, judged by size and the histological appearance. Radical prostatectomy is strongly suggested as appropriate therapy for this group.Supported in part by a Grant from the Ministry of Education (art. 286 T.U., 1977/78)